
## Lawrence Park

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5540081/publications.pdf Version: 2024-02-01



LANDENCE DADK

#	Article	IF	CITATIONS
1	Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biological Psychiatry, 2017, 81, 886-897.	1.3	334
2	Depression in the Primary Care Setting. New England Journal of Medicine, 2019, 380, 559-568.	27.0	206
3	Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Molecular Psychiatry, 2019, 24, 1040-1052.	7.9	187
4	Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. Biological Psychiatry, 2018, 84, 582-590.	1.3	123
5	Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. Journal of Affective Disorders, 2017, 218, 195-200.	4.1	94
6	Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. Journal of Affective Disorders, 2018, 232, 310-315.	4.1	87
7	Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. CNS Drugs, 2021, 35, 527-543.	5.9	74
8	Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties. Biological Psychiatry, 2017, 82, 361-369.	1.3	68
9	Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. Journal of Affective Disorders, 2018, 231, 51-57.	4.1	62
10	Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. Journal of Affective Disorders, 2020, 263, 568-575.	4.1	59
11	Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. International Journal of Neuropsychopharmacology, 2021, 24, 8-21.	2.1	58
12	Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. Journal of Clinical Psychiatry, 2017, 78, 1068-1074.	2.2	55
13	Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Molecular Psychiatry, 2018, 23, 1626-1631.	7.9	48
14	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. Molecular Psychiatry, 2021, 26, 4085-4095.	7.9	48
15	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology, 2020, 45, 1398-1404.	5.4	47
16	Characterizing the course of suicidal ideation response to ketamine. Journal of Affective Disorders, 2018, 241, 86-93.	4.1	44
17	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. International Journal of Neuropsychopharmacology, 2020, 23, 417-425.	2.1	42
18	Ketamine treatment for depression: a review. Discover Mental Health, 2022, 2, 9.	2.0	37

LAWRENCE PARK

#	Article	IF	CITATIONS
19	Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2019, 22, 10-18.	2.1	27
20	Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues. BMC Psychiatry, 2019, 19, 332.	2.6	24
21	Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion. Biological Psychiatry, 2017, 82, e35-e36.	1.3	20
22	Can â€~floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. Journal of Psychiatric Research, 2020, 130, 280-285.	3.1	18
23	Ketamine for Treatment-Resistant Mood Disorders. Focus (American Psychiatric Publishing), 2019, 17, 8-12.	0.8	16
24	The effects of ketamine on typical and atypical depressive symptoms. Acta Psychiatrica Scandinavica, 2020, 142, 394-401.	4.5	16
25	Are 24-hour motor activity patterns associated with continued rapid response to ketamine?. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2739-2748.	2.2	14
26	Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. Journal of Affective Disorders, 2021, 280, 136-139.	4.1	14
27	Depression in the Primary Care Setting. New England Journal of Medicine, 2019, 380, 2278-2280.	27.0	12
28	Active suicidal ideation during clinical antidepressant trials. Psychiatry Research, 2017, 257, 303-308.	3.3	9
29	Panic probes and the identification of panic: a historical and cross-cultural perspective. Culture, Medicine and Psychiatry, 2002, 26, 137-153.	1.2	8
30	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration. Translational Psychiatry, 2022, 12, 179.	4.8	8
31	Symptom trajectories in the months before and after a suicide attempt in individuals with bipolar disorder: A STEPâ€BD study. Bipolar Disorders, 2020, 22, 245-254.	1.9	7
32	Neurobiological research with suicidal participants: A framework for investigators. General Hospital Psychiatry, 2020, 62, 43-48.	2.4	7
33	The relationship between the HDRS insomnia items and polysomnographic (PSG) measures in individuals with treatment-resistant depression. Journal of Psychiatric Research, 2022, 148, 27-33.	3.1	7
34	The mental health impact of contact with COVID-19 patients on healthcare workers in the United States. Psychiatry Research, 2022, 308, 114359.	3.3	5
35	Case 14-2008. New England Journal of Medicine, 2008, 358, 2051-2059.	27.0	3
36	Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. Journal of Clinical Psychopharmacology, 2018, 38, 243-246.	1.4	3

LAWRENCE PARK

#	Article	IF	CITATIONS
37	Key considerations in the pharmacological management of treatment-resistant depression. Expert Opinion on Pharmacotherapy, 2021, 22, 2405-2415.	1.8	3
38	Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status― CNS Drugs, 2022, 36, 205-206.	5.9	3
39	Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects. Journal of Psychiatric Research, 2017, 86, 55-57.	3.1	2
40	F170. Monoamine Oxidase Inhibitor Use in an Adult Patient With Treatment Resistant Depression. Biological Psychiatry, 2018, 83, S304.	1.3	1
41	Reply. Pain, 2016, 157, 1175-1176.	4.2	0
42	517. Effects of Ketamine on Atypical and Typical Symptoms of Depression. Biological Psychiatry, 2017, 81, S210.	1.3	0
43	416. The KET-MOA Study: New Findings into the Neurobiology of the Response/non-Response, and Relapse Processes. Biological Psychiatry, 2017, 81, S170.	1.3	0
44	861. Mood Dependent Effects of Ketamine on REM Eye Movements in Patients with Treatment Resistant Depression (TRD). Biological Psychiatry, 2017, 81, S348-S349.	1.3	0
45	Reply to: "Letter to the Editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of Lightnessare not the same – A comment on Acevedo-Diaz et al.―(Jpsychiatrres-D-21-00121). Journal of Psychiatric Research, 2021, 137, 409-410.	3.1	0